DURECT Corporation, Near Term PDUFA Dates, Pipeline Review and Analysts Target

NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on DURECT Corporation (NASDAQ: DRRX), a biopharmaceutical company developing therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms. DUR‑928, a new chemical entity in Phase 1 development, is the lead candidate in DURECT’s Epigenetic Regulator Program.

DRRX latest clinical update, upcoming PDUFA dates, and other potential catalysts READ MORE.

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/durect/

On May 9th, the company announced it has entered into an amendment to the development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS), regarding POSIMIR® (SABER®-bupivacaine) in the United States. Pursuant to the amended agreement, DURECT is now eligible for up to $30 million in milestone payments based on NDA approval and remains eligible for up to an additional $230 million in sales-based milestones.

Pipeline overview and the analyst’s target price here READ MORE.

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/durect/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 506209